SPLASH BEVERAGE GROUP, INC. — Form 8-K/A
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 68/100
What the filing says
Splash Beverage amended its exclusive license agreement with Argent BioPharma (dated July 28, 2026) to expand CannEpil's field from human epilepsy treatment to include veterinary applications (companion-animal oncology and chronic pain). Royalty rates were reduced from 15% to 10% for veterinary net revenues. Splash is partnering with Lupvindol UK Limited for FDA Center for Veterinary Medicine INAD/Conditional Approval development; various contractual deadlines extended from 90 to 120 days. No upfront payment amount disclosed; no share issuance mentioned.
Why this rating
Meaningful expansion of IP scope and partnership for $6.5M-cap company; substantial TAM (vet pain $3.8B by 2030, oncology $900M–$1.7B) but early-stage, high-regulatory-risk, pre-revenue program. Reduces royalty burden (10% vs 15%) but IP value unproven.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.